

Alfredo Budillon

Dr Alfredo Budillon is the Scientific Director of “Istituto Nazionale Tumori IRCCS G. Pascale” of Naples, Italy since June 2022.

He has a Medical Degree & Board Certification (1989), a PhD Degree in Oncology (1996), the Medical Oncology Specialty Certification (1997), and a Master Degree in Health Economy, Management and Bioethics (2001).

Dr Budillon joined Istituto G. Pascale, in 1996 after a post-doctoral experience of six years at the National Cancer Institute, N.I.H., Bethesda, M.D., U.S.A. (from 1990 to 1995), where he gained experience in biochemistry and antitumor experimental therapeutics.

At Pascale Institute Dr Budillon has been Director of Experimental Pharmacology Unit from June 2005 to June 2022, being also in charge of the NMR Metabolomics Facility, the high-throughput and high-content screening facility and the Animal Facility at the Institute’s Oncology Research Center of Mercogliano (CROM) of IRCCS Pascale.

His major areas of expertise and interest are:

- preclinical and clinical development of new anti-tumor therapeutic approaches, particularly in gastrointestinal cancer (colorectal and pancreatic cancer), through new drug combinations and drug repositioning as well as early clinical trials;
- identification of new prognostic and/or predictive markers of response and therapeutic targets by means of flow cytometry, proteomic and metabolomic analysis;
- patient ‘engagement in clinical research;
- education and training

He is coordinator and partner of several national and international research projects, mainly in oncology.

Dr Budillon is currently Chair of “Small Molecules” Platform of EATRIS, European Infrastructure for Translational Medicine (EATRIS), and member of the A-IATRIS Board of Directors, the Italian node of EATRIS.

He is Member of the Ethical Committee Campania 2.

He is member the of the Board of Directors, DFM (Molecular Diagnostics and Pharmaceuticals) Scarl, Research Consortium, Naples; member of Board of Directors of PM4CARE (research infrastructure on Precision Medicine) Scarl, Naples, Italy; president of the Board of Director of Campania Oncoterapie Scarl research consortium, Naples, Italy.

He is Member of the academic board of the PhD program in Biomedical Science and Biotechnology, Vanvitelli University, Napoli, Italy.

Dr Budillon has Italian National Qualification as Full Professor of Medical Oncology; of Health professions and applied medical technologies; of General Pathology.

He is Author of over 200 articles published in peer reviewed journals and of two international diagnostic tools patents as well as of several other scientific publications and chapters of books on clinical and translational oncology topics.

The Career H-Index Scopus (2024) is 53 (>8000citations);